Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. Class H

HHKEX:9887
32.20
HKD
-1.06
(-3.19%)
-0.97EPS
Mar 29Next Earn
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.05
- -
1.02
- -
Basic EPS, GAAP
-1.92
-1.6
-1.21
-0.88
Free Cash Flow per Basic Share
-1.08
-0.65
-0.95
-0.54
Dividend per Share
- -
- -
- -
- -
Book Value per Share
-5.03
1.41
6.36
0.56
Tangible Book Value per Share
-5.03
1.41
6.36
0.55
Basic Weighted Avg Shares
189
189
174
189
Sales/Revenue/Turnover
9
- -
177
- -
Operating Margin (%)
-2,922.57
- -
-108.91
- -
Depreciation Expense
24
26
21
11
Net Income, GAAP
-362
-301
-211
-166
Effective Tax Rate (%)
- -
- -
- -
- -
Profit Margin (%)
-4,086.28
- -
-119.27
- -
Working Capital
-1,027
198
1,188
37
LT Debt
2
6
13
12
Total Equity
-949
266
1,266
105
Return on Invested Capital (%)
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-27.61
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'24
Jun'25
ST Debt
- -
288
LT Borrowings
- -
- -
LT Finance Leases
- -
12
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
143
189
Market Capitalization
- -
- -

Working Capital

CNY

•

in mil. unless spec.
Jun'24
Jun'25
Total Current Assets
- -
550
Cash, Cash Equivalents & STI
- -
452
Accounts Receivable, Net
- -
- -
Inventories
- -
31
Total Current Liabilities
- -
514
Payables & Accruals
- -
- -
ST Debt
- -
288
Deferred Revenue
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
376.66%
Free Cash Flow
- -
- -
35.35%
Net Income, GAAP
- -
- -
-29.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
177
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.6
2025
- -
- -
-1.21
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Xiao Qiang Kang
Full Time Employees
244
Sector
Health technology
Industry
Biotechnology
Address
Building 03 Nanjing JS China 210019
IPO Date
Jul 25, 2025
Business
Nanjing Leads Biolabs Co., Ltd. (9887.HK) is a clinical-stage biotechnology company engaged in the discovery, development, and commercialization of novel antibody drugs targeting oncology, autoimmune diseases, and other severe conditions; its core pipeline includes Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), and gastric cancer (GC); LBL-034, a GPRC5D/CD3 bispecific T-cell engager for multiple myeloma; LBL-033 and LBL-007, additional bispecific antibodies; LBL-051, a CD19/BCMA/CD3 tri-specific T-cell engager for autoimmune indications; and other preclinical candidates leveraging proprietary platforms such as LeadsBody (CD3 T-cell engager), X-body (4-1BB engager), and TOPiKinetics-ADC for antibody-drug conjugates. The company operates primarily in China with global development ambitions and maintains research facilities in Nanjing. Founded in 2012 and headquartered at Building 03, Floor 8, No. 18 East Jialingjiang Street, Nanjing, Jiangsu Province, China, Nanjing Leads Biolabs listed on the Main Board of The Stock Exchange of Hong Kong Limited in July 2025, raising approximately USD 189 million through its initial public offering to fund clinical trials and R&D; in November 2024, it formed Oblenio Bio, Inc. with Aditum Bio, granting an exclusive worldwide license option for LBL-051 and securing up to USD 35 million in upfront and near-term payments plus USD 579 million in milestones and royalties along with an equity stake; in October 2025, it entered a collaboration with Dianthus Therapeutics worth up to USD 1 billion for ex-China rights to an undisclosed autoimmune asset, including USD 30 million upfront and near-term milestones; recent clinical advancements feature LBL-024 receiving FDA Orphan Drug Designation in November 2024 for neuroendocrine carcinoma, Phase Ib/II data presentations at ASCO 2025 and ASH 2024 for LBL-034, and LAG-3 antibody LBL-007 results published in the Journal of Hematology & Oncology in February 2025.